CD79B and Burkitt lymphoma: A recent small case series reported the treatment of three patients with chemo-refractory BL, including one with secondary CNS involvement, with CD20xCD3 bispecific antibody glofitamab in combination with CD79b-targeting antibody drug conjugate polatuzumab vedotin [15].